PhageNova Bio Competitors and Similar CompaniesClear all

ARIAD Pharmaceuticals's competitors and similar companies include Exelixis, TRON and PharmaEssentia.

	ARIAD Pharmaceuticals ARIAD Pharmaceuticals is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers.	Exelixis Exelixis is an oncology company that develops cancer treatments.	TRON TRON Mainz is a biopharmaceutical research organization that offers diagnostics and drugs for the treatment of cancer and other severe diseases.	PharmaEssentia PharmaEssentia (藥華醫藥股份有限公司) is a biotech company focused on the areas of hematology, oncology, dermatology, and infectious diseases.
Founding Date	Founding Date 1991	Founding Date 1994	Founding Date 2010	Founding Date 2003
Type	Type Subsidiary	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Cambridge, US HQ Boston, US Chicago, US Cincinnati, US Dallas, US Minneapolis, US New York, US see more	Locations Alameda, US HQ	Locations Mainz, DE HQ	Locations Taipei, TW HQ Shinjuku City, JP Burlington, US
Employees	Employees 1381% increase	Employees 1,14712% decrease	Employees 1903% increase	Employees 4897% increase
Financial
Revenue (est.)	Revenue (est.) $118.8m (FY, 2015)	Revenue (est.) $2.3b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) NT$15.6b (FY, 2025)
Cost of goods	Cost of goods $2.1m (FY, 2015)	Cost of goods $83.7m (FY, 2025)	Cost of goods N/A	Cost of goods NT$1.3b (FY, 2025)
Gross profit	Gross profit $116.7m (FY, 2015)	Gross profit $2.2b (FY, 2025)	Gross profit N/A	Gross profit NT$14.4b (FY, 2025)
Net income	Net income ($231.2m) (FY, 2015)	Net income $782.6m (FY, 2025)	Net income N/A	Net income NT$5b (FY, 2025)